Vorapaxar and Amyotrophic Lateral Sclerosis: Coincidence or Adverse Association?
Sign Up to like & getrecommendations! Published in 2017 at "American Journal of Therapeutics"
DOI: 10.1097/mjt.0000000000000395
Abstract: Background: Vorapaxar, a novel antiplatelet thrombin PAR-1 inhibitor, is currently approved for post myocardial infarction and peripheral artery disease indications with concomitant use of clopidogrel and/or aspirin. The vorapaxar safety profile was acceptable. However, aside… read more here.
Keywords: adverse association; association vorapaxar; vorapaxar; association ... See more keywords
No benefit of vorapaxar on walking performance in patients with intermittent claudication
Sign Up to like & getrecommendations! Published in 2021 at "Vascular Medicine"
DOI: 10.1177/1358863x211042082
Abstract: Background: The effect of pharmacologic agents in improving walking and quality of life measures in patients with intermittent claudication (IC) is variable. The objective of this study was to investigate the effect of the novel… read more here.
Keywords: patients intermittent; benefit vorapaxar; vorapaxar; walking performance ... See more keywords